Security Notice: Please be aware of impersonation attempts using our company name

Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.

Quick Order

Account

New to ASCENT?

Cart

Promotion Products Primary Cells

Immortalized Cells

Cancer (Tumor) Cell Lines

Genome-edited Cells

Media and Reagents

Organoids Uncategorized

Case Study

Case studies contain reports on ASCENT's exploration of the underlying mechanisms of cell states, including cell growth, cell differentiation, and even cell death.

Experiment Applications

Preclinical Applications

Area of Research Interest

Industry

Case Study

Case studies contain reports on ASCENT's exploration of the underlying mechanisms of cell states, including cell growth, cell differentiation, and even cell death.

Applications

Articles

Brochures and Flyers

Protocols and Tips

Four Points You May Consider to Generate a Stable Cell Line

Case Study

Our Product in Research

Ascent Progress

Case Study

Case studies contain reports on ASCENT's exploration of the underlying mechanisms of cell states, including cell growth, cell differentiation, and even cell death.

Home / Products / Genome-edited Cells / Knockout Cell Lines / BMP2 Knockout 786-O Polyclonal Cells

Cat. No. ARG35177

BMP2 Knockout 786-O Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Kidney
Disease:
Renal cell carcinoma

Datasheet

BMP2 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human clear cell renal carcinoma line 786-O. This model disrupts the BMP2 gene, which encodes a TGF-beta superfamily ligand that signals through BMPR1A/B and BMPR2 receptors to activate SMAD1/5/8 and regulate targets like ID1 and RUNX2. These cells provide a tool to study BMP2??s role in ccRCC progression, EMT, and bone metastasis within a VHL-mutant context. Applications include proliferation assays, phospho-SMAD analysis, and transcriptomic profiling.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

786-O

Sex of Donor

Male

Age

58 years

Derived From Site

In situ; Kidney

Gene Name

BMP2

Gene Identifier

NCBI Gene ID 650

Morphology

Epithelial-like

Growth Mode

Adherent

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

RPMI 1640

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

BMP2 Knockout 786-O Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population derived from the 786-O human renal cell carcinoma line, featuring targeted disruption of the BMP2 gene. BMP2 encodes a secreted TGF-beta superfamily ligand involved in osteoblast differentiation, bone formation, and embryonic development. This polyclonal cell pool eliminates the need for single-cell cloning, enabling direct loss-of-function analysis in a mixed edited population.

The 786-O line is a well-characterized model of clear cell renal cell carcinoma (ccRCC), harboring a mutant VHL gene that drives constitutive HIF activation. This epithelial tumor cell line is widely employed to study renal cancer biology, providing a clinically relevant platform to investigate how BMP2 disruption affects tumorigenic properties under VHL-deficient conditions.

BMP2 signals through heteromeric complexes of type I (ALK3/BMPR1A, ALK6/BMPR1B) and type II (BMPR2) serine/threonine kinase receptors, leading to phosphorylation of SMAD1/5/8. These R-SMADs complex with SMAD4 and translocate to the nucleus, regulating transcription of target genes such as ID1, ID2, DLX5, RUNX2, ALP, and OCN. Signaling is modulated by extracellular antagonists (Noggin, Chordin, Gremlin) and intersects with non-canonical MAPK (ERK, p38) and PI3K-Akt pathways. Upstream regulators include retinoic acid, Hedgehog, Wnt, and inflammatory cytokines like TNF-alpha and IL-1beta.

In the 786-O context, BMP2 can influence cell proliferation, migration, and epithelial-mesenchymal transition, contributing to ccRCC progression and potential bone metastasis. Knocking out BMP2 in these cells allows dissection of its role in VHL-mutant renal carcinoma, including crosstalk with pathways such as Wnt and Hedgehog. Moreover, because BMP2 is critical for bone homeostasis, this model is pertinent for investigating tumor?Cbone microenvironment interactions and osteolytic or osteoblastic lesion mechanisms.

Researchers can utilize these polyclonal knockout cells for western blotting of BMP2 and phospho-SMAD1/5, RT-qPCR of downstream genes, cell proliferation and migration assays, alkaline phosphatase activity measurements, and RNA-seq to profile transcriptomic changes. Co-culture systems with osteoblasts or bone matrices can assess metastatic potential. For further information, please contact Ascent Research.